We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+1.09%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$101M
AUM Growth
-$14.5M
Cap. Flow
-$1.16M
Cap. Flow %
-1.15%
Top 10 Hldgs %
56.77%
Holding
80
New
12
Increased
15
Reduced
13
Closed
9

Top Buys

Rank Stock Value
1
KLAC icon
KLA
KLAC
+$11.9M
2
OVV icon
Ovintiv
OVV
+$2.03M
3
NVCR icon
NovoCure
NVCR
+$1.22M
4
PRTA icon
Prothena Corp
PRTA
+$886K
5
GPCR icon
Structure Therapeutics
GPCR
+$792K

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$17.8M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$1.41M
3
UTHR icon
United Therapeutics
UTHR
+$971K
4
TVTX icon
Travere Therapeutics
TVTX
+$580K
5
MASI
Masimo
MASI
+$479K

Sector Composition

Rank Sector Weight
1 Healthcare 79.06%
2 Technology 14.1%
3 Energy 6.07%
4 Materials 0.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CADL icon
51
Candel Therapeutics
CADL
$716M
$304K 0.3%
60,000
– –
TELA icon
52
TELA Bio
TELA
$32.2M
$301K 0.3%
155,000
– –
COGT icon
53
Cogent Biosciences
COGT
$6.55B
$287K 0.29%
+40,000
New +$222K
WVE icon
54
Wave Life Sciences
WVE
$1.1B
$262K 0.26%
40,300
– –
TXG icon
55
10x Genomics
TXG
$5.47B
$255K 0.25%
22,000
-28,000
-56% -$255K
APLS
56
DELISTED
Apellis Pharmaceuticals
APLS
$242K 0.24%
14,000
– –
PHAT icon
57
Phathom Pharmaceuticals
PHAT
$849M
$240K 0.24%
+25,000
New +$138K
BBIO icon
58
BridgeBio Pharma
BBIO
$15.9B
$216K 0.21%
+5,000
New +$182K
NPCE icon
59
Neuropace
NPCE
$536M
$183K 0.18%
16,442
– –
GOSS icon
60
Gossamer Bio
GOSS
$71.2M
$170K 0.17%
138,176
– –
FOLD
61
DELISTED
Amicus Therapeutics
FOLD
$160K 0.16%
28,000
– –
ZBIO
62
Zenas BioPharma
ZBIO
$1.97B
$160K 0.16%
16,500
– –
CGEM icon
63
Cullinan Oncology
CGEM
$1.08B
$151K 0.15%
20,000
– –
KPTI icon
64
Karyopharm Therapeutics
KPTI
$165M
$121K 0.12%
27,985
– –
APLT
65
DELISTED
Applied Therapeutics
APLT
$87.1K 0.09%
+280,000
New +$108K
VTYX
66
DELISTED
Ventyx Biosciences
VTYX
$61.6K 0.06%
28,800
– –
IFRX icon
67
InflaRx
IFRX
$268M
$39.5K 0.04%
50,000
– –
APVO icon
68
Aptevo Therapeutics
APVO
$5.94M
$30.5K 0.03%
+556
New +$101K
ALMS
69
Alumis Inc
ALMS
$3.59B
$30K 0.03%
10,000
– –
ZNTL icon
70
Zentalis Pharmaceuticals
ZNTL
$361M
$19.7K 0.02%
17,000
– –
AXDX
71
DELISTED
Accelerate Diagnostics
AXDX
$2.08K ﹤0.01%
325,239
– –
ARVN icon
72
Arvinas
ARVN
$517M
– –
-30,000
Closed -$211K
ATRA icon
73
Atara Biotherapeutics
ATRA
$74.3M
– –
-22,000
Closed -$131K
CMPX icon
74
Compass Therapeutics
CMPX
$364M
– –
-24,000
Closed -$45.6K
KROS icon
75
Keros Therapeutics
KROS
$209M
– –
-15,000
Closed -$153K
1 2
3
4

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q2 2025 Portfolio in Review

As of Q2 2025, Birchview Capital held 80 positions worth $101M, down 13% from $115M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Birchview Capital's Q2 2025 filing shows 12 new, 15 increased, 13 reduced and 9 closed positions. Its largest new stake was KLA: 158,480 shares worth $14.2M. The largest sale was Bristol-Myers Squibb, an estimated $17.8M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, down from 96% a quarter earlier, followed by Technology and Energy.

  • Birchview Capital's largest Q2 2025 buy was KLA: 158,480 shares worth $14.2M.
  • Birchview Capital added most to Ovintiv in Q2 2025, an estimated $2.03M increase.
  • Birchview Capital's biggest Q2 2025 reduction was Bristol-Myers Squibb, cutting an estimated $17.8M.
  • Birchview Capital fully exited SpringWorks Therapeutics in Q2 2025, selling an estimated $365K.
  • Birchview Capital's ten largest holdings make up 57% of its $101M portfolio in Q2 2025.
  • Birchview Capital opened 12 new positions and closed 9 in Q2 2025.
  • Birchview Capital's portfolio value fell 13% quarter-over-quarter to $101M.

Based on Birchview Capital's 13F filing for Q2 2025, filed 14 Aug 2025.